Results
FT3 levels at admission were considerably lower in poor outcome patients
than those with good outcome at 3 months (3.53±0.70pmol/L vs
4.04±0.68pmol/L, respectively; P<0.001). Lower levels of FT3 were
observed with higher mRS scores. Multivariable logistic regression
analysis revealed that FT3 levels were significantly associated with
risk of poor outcome at 3 months independent of conventional risk
factors such as age, NIHSS score and recanalized therapy. In addition,
patients in the bottom quartile of FT3 levels had a 2.56-fold higher
risk of developing poor outcome compared with patients in the top
quartile (OR=2.56; 95%CI 1.15-5.69, p =0.021). The sensitivity and
specificity of FT3 (≤3.69pmol/L) predicting poor outcome were 62.70%
and 72.03% respectively.